Biodesix Announces First Quarter 2026 Results and Highlights
Biodesix reported strong Q1 2026 results with revenue growing 42% year-over-year to $25.6 million, driven by a 29% increase in test volumes and a doubling of Development Services revenue. Gross margin was 84% (82% excluding a one-time tax recovery), and the company raised its full-year 2026 revenue guidance to $108-114 million, representing 25% growth at the midpoint.
Key figures
- Guidance
- FY 2026 revenue $108-114 million (midpoint reflects 25% growth)
- Revenue Yoy
- 42%
- Atm proceeds
- 16800000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.